Modular therapy approach in metastatic castration-refractory prostate cancer
- 19 May 2010
- journal article
- research article
- Published by Springer Nature in World Journal of Urology
- Vol. 28 (6) , 745-750
Abstract
The present multi-center phase II study was designed to support the hypothesis that networking agents, which bind to ubiquitous accessible targets in metastatic castration-refractory prostate cancer (CRPC) may counteract neoplasia-specific aberrant cellular functions, thereby mediating PSA response (primary endpoint). Patients with metastatic CRPC received low-dose chemotherapy with capecitabine 1 g twice daily plus dexamethasone 1 mg daily for 14 days every 3 weeks, COX-2 blockade with rofecoxib 25 mg (or etoricoxib 60 mg) daily combined with pioglitazone 60 mg daily until disease progression. Thirty-six consecutive patients with metastatic CRPC were enrolled, of whom n = 18 (50%) had been extensively pretreated with radio- or radionuclid therapy and n = 16 (44%) with chemotherapies; n = 8 patients (22%) were medically none-fit, having an ECOG-score of 0–2. Nine of 15 patients with PSA response >50% showed objective response. Median time to PSA response was 2.4 months (range 1.0–7.3 months). Two of 9 patients responding with PSA < 4 ng/ml showed complete resolution of skeletal lesions after 9 and 16 months; 13 patients had a stable course of disease, and 5 patients experienced progressive disease. Median progression-free survival (PFS) was 4.0 months (2.8–5.1 months) and median overall survival (OS) 14.4 months (10.7–17.2 months). Toxicities according to WHO grade II were noticed in 9 patients. This new combined modular therapy approach is able to induce major responses including resolution of skeletal lesions in patients with CRPC. Furthermore, the study may clinically support the above-mentioned hypothesis.Keywords
This publication has 27 references indexed in Scilit:
- Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant MelanomaPPAR Research, 2009
- Principles of Modular Tumor TherapyCancer Microenvironment, 2009
- Phase I Study of Ixabepilone, Mitoxantrone, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Therapy: A Study of the Department of Defense Prostate Cancer Clinical Trials ConsortiumJournal of Clinical Oncology, 2009
- Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine featuresAnnals of Oncology, 2009
- Thiazolidinediones regulate expression of cell cycle proteins in human prostate cancer cells via PPARγ-dependent and PPARγ-independent pathwaysCell Cycle, 2009
- PPARγ2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cellsJournal of Cellular Biochemistry, 2008
- Systems Biology: A Therapeutic Target for Tumor TherapyCancer Microenvironment, 2008
- Peroxisome Proliferator‐Activated Receptor‐γ Is a Potent Target for Prevention and Treatment in Human Prostate and Testicular CancerPPAR Research, 2008
- COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trialThe Lancet Oncology, 2007
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007